ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 427

Epigenetic Features As Predictive Markers of Responsiveness to Epitope-Specific Therapy in Rheumatoid Arthritis

Roberto Spreafico1, Maura Rossetti1, Theodorus Van Der Broek1, Olivia Morrow1 and Salvatore Albani2, 1Translational Immunology, Sanford-Burnham Medical Research Institute, La Jolla, CA, 2Translational Research Program, Infectious and Inflammatory Diseases, Sanford-Burnham Medical Research Institute, La Jolla, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: biomarkers and rheumatoid arthritis, pathogenesis

Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenisis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The focus of current research for new therapeutic approaches in Rheumatoid arthritis (RA) is shifting from mere suppression to induction and maintenance of tolerance. Adaptive immunity, specifically the balance and functions of effector and regulatory CD4+ T cells, is central in this context. We have recently developed a protocol of oral tolerance induction to an epitope (dnaJP1) derived from a heat shock protein (HSP), a key component of the mechanism of perpetuation and amplification of chronic autoimmune inflammation. Phase II trial results showed clinical efficacy and an intriguing immune deviation of T cell immunity. In order to dissect further the mechanism of action and also to identify biomarkers predictive of susceptibility to treatment, we employed here whole genome DNA methylation analysis, which can be correlated to gene expression and is relatively more stable compared to mRNA, the basis of the well-known whole transcriptome analysis.

Methods:

Total CD4+ T cells from 12 patients taken at baseline, equally segregated in placebo responders/non-responders (R/NR) and HSP peptide R/NR, were sorted from PBMCs. DNA was extracted and bisulfite converted to analyze the cytosine methylation pattern. Converted DNA was analyzed using Illumina Infinium HumanMethylation450 BeadChip, yielding the methylation percentage of more than 485,000 CpG sites across the genome.

Results:

A nearly perfect segregation of R and NR was observed when Principal Component Analysis (PCA) was applied to the whole dataset. When sites selected for discriminating R from NR (based on p-value and fold change) were used, PCA was also able to discriminate, based on average DAS-28 scores, weak responders from strong responders. Weak responders were more frequent among placebo treated subjects, while HSP peptide-treated subjects comprised stronger responders. In order to enrich for sites discriminating R and NR with high confidence without losing power due to the high number of CpG sites, pre-filtering of sites with low variance was performed. With this method, we found 51 sites differentially methylated between R and NR, clearly  supporting the potential of the whole genome methylation analysis for discovery of new candidate biomarkers. As a control, mock comparisons, such as between all placebo against all HSP peptide-treated subjects irrespective of clinical outcome (which is not meaningful at baseline due to patient randomization) were run and consistently yielded fewer hits. 

Conclusion:

We found significant differences in the general pattern of DNA methylation between RA patients responding or not responding to an epitope-specific therapy. We have also identified a set of CpG sites with high predictive and prognostic power for discriminating the responsiveness to treatment, which may be developed as a screening tool. The functions of the genes found to be differentially methylated is currently under investigation.


Disclosure:

R. Spreafico,
None;

M. Rossetti,
None;

T. Van Der Broek,
None;

O. Morrow,
None;

S. Albani,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epigenetic-features-as-predictive-markers-of-responsiveness-to-epitope-specific-therapy-in-rheumatoid-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology